OS THERAPIES INCORPORATED Increase (Decrease) in Employee Related Liabilities
OS THERAPIES INCORPORATED (OSTX) reported Increase (Decrease) in Employee Related Liabilities of -$41.85 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2025-11-14
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for the quarter ending 2025-03-31 was -$96.99K.
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for the quarter ending 2024-12-31 was $29.08K.
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for the quarter ending 2024-09-30 was -$15.37K.
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for the quarter ending 2024-06-30 was -$8.48K.
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for fiscal 2024 was -$48.42K.
- OS THERAPIES INCORPORATED increase (decrease) in employee related liabilities for fiscal 2023 was -$280.33K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 6 month as first filed | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 9 month as first filed | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | -$41.85K 10-Q · filed 2025-11-14 | |||||
| 2025-03-31 | -$96.99K 10-Q · filed 2025-05-15 | -$67.91K derived: sum of 2 quarters · filed 2025-05-15 | -$83.28K derived: sum of 3 quarters · filed 2025-11-14 | -$91.76K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-12-31 | $29.08K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.70K derived: sum of 2 quarters · filed 2025-11-14 | $5.22K derived: sum of 3 quarters · filed 2025-11-14 | -$48.42K 10-K · filed 2025-03-31 | ||
| 2024-09-30 | -$15.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$23.85K derived: sum of 2 quarters · filed 2025-11-14 | -$77.50K 10-Q · filed 2025-11-14 | -$134.65K 10-Q · filed 2024-11-15 | -$185.40K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$8.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$62.13K 10-Q · filed 2025-08-18 | -$31.25K 10-Q · filed 2024-08-14 | -$170.03K derived: sum of 3 quarters · filed 2025-08-18 | -$286.38K derived: sum of 4 quarters · filed 2025-08-18 | |
| 2024-03-31 | -$53.65K 10-Q · filed 2025-05-15 | -$161.55K derived: sum of 2 quarters · filed 2025-05-15 | -$277.90K derived: sum of 3 quarters · filed 2025-05-15 | -$381.01K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$107.90K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$224.25K derived: sum of 2 quarters · filed 2025-03-31 | -$327.36K derived: sum of 3 quarters · filed 2025-03-31 | -$280.33K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$116.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | -$219.46K derived: sum of 2 quarters · filed 2024-11-15 | -$172.43K 10-Q · filed 2024-11-15 | |||
| 2023-06-30 | -$103.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$56.08K 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $47.03K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |